Cencora, Inc. (NYSE:COR) Stake Boosted by Boston Partners

Boston Partners lifted its holdings in Cencora, Inc. (NYSE:COR) by 2.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 5,007,100 shares of the company’s stock after purchasing an additional 125,611 shares during the period. Cencora makes up approximately 1.4% of Boston Partners’ holdings, making the stock its 4th largest holding. Boston Partners’ holdings in Cencora were worth $1,128,058,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of COR. Generali Asset Management SPA SGR acquired a new stake in Cencora during the fourth quarter worth about $6,279,000. Evoke Wealth LLC increased its position in Cencora by 12.3% during the fourth quarter. Evoke Wealth LLC now owns 2,075 shares of the company’s stock worth $466,000 after purchasing an additional 228 shares during the last quarter. Cozad Asset Management Inc. increased its position in Cencora by 64.1% during the fourth quarter. Cozad Asset Management Inc. now owns 3,815 shares of the company’s stock worth $857,000 after purchasing an additional 1,490 shares during the last quarter. Counterpoint Mutual Funds LLC increased its position in shares of Cencora by 79.3% during the fourth quarter. Counterpoint Mutual Funds LLC now owns 6,136 shares of the company’s stock valued at $1,379,000 after acquiring an additional 2,713 shares during the last quarter. Finally, Signaturefd LLC increased its position in shares of Cencora by 8.4% during the fourth quarter. Signaturefd LLC now owns 3,614 shares of the company’s stock valued at $812,000 after acquiring an additional 279 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

COR has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Mizuho started coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. Evercore ISI lifted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Wells Fargo & Company lifted their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a report on Friday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $280.20.

Insiders Place Their Bets

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the transaction, the chief executive officer now directly owns 51,070 shares in the company, valued at $13,022,850. The trade was a 8.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,648 shares of company stock valued at $3,382,462. 10.80% of the stock is owned by corporate insiders.

Cencora Trading Up 1.1 %

NYSE COR opened at $260.98 on Tuesday. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $263.70. The firm has a 50 day moving average of $248.23 and a two-hundred day moving average of $239.31. The stock has a market capitalization of $50.61 billion, a PE ratio of 37.12, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.84%. Cencora’s payout ratio is currently 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.